Growth Rate Of Cardiac Medicine Market In The Last Decade

The cardiac medicine market in India is seen as a fast growing segment of the overall picture. This is actually part of the pharmaceutical industry between 2014 and 2024. The whole cardiovascular drug landscape in the country changed if you notice over the past decade. This is because of the rising prevalence of cardiovascular disease and earlier diagnosis. People now have more access to treatment which also shapes the growth.

Between 2014 and 2024 was the time when India’s hear medicine industry transitioned. It went from steady expansion to growth that’s sustained as well as double digit. This is what positions cardiac therapies as a strategic pillar. It can be noticed within the broader Indian pharmaceutical market.

Cardiac Medicine Market in India: 10 Year Growth Snapshot (2014 to 2024)

If we look at the industry data, things become more confirmed. It’s interesting to think about how the cardiac medicine market in India has more than tripled in value over the last decade.

According to reporting by The Economic Times,

The combined cardiac and diabetes drug market which was about ₹10,000 crore in 2014 has grown. It reached nearly ₹30,000 crore by 2024 which is what reflects 3X expansion in ten years.

If we go further, then Business Standard has also reported some data. According to that, the cardiac medication sales have grew by about 50% between 2021 and 2025. This shows that they are rising from ₹1,761 crore to ₹2,645 crore. With this, it’s possible for the annual growth to be about 10.7%.

What Are The Key Drivers Behind Cardiac Medicine Market Growth in India?

Between 2014 and 2024, the expansion that you see of the cardiovascular drug market isn’t random. There are actually a lot of structural health and economic shifts that drove it.

Rising Cardiovascular Disease Burden

India is a country that faces a lot of hypertension. These include the prevalence of coronary artery disease and heart failure which continue to rise. This is evident if you consider various public health reviews. But things change as screening improves which makes people more aware. Now patients are entering long term treatment plans which increases the demand as well.

Longer Treatment Cycles

Cardiac medications aren’t exactly like acute therapies as well. This is because a medication like this is mostly prescribed for life. With this, you get a cumulative and compounding demand. Over the years, each new diagnosis adds sustained consumption.

Expanding Pharma Distribution Infrastructure

With better domestic production it’s natural for the distribution networks to get stronger. This has ensured that cardiac medications are more accessible. This is included in Tier 2 and Tier 3 cities. Greater accessibility is what directly feeds market expansion.

Preventive Cardiology & Early Intervention

It’s not wrong to say that clinical practice has shifted into intervention that’s early. Physicians now also prescribe statins and blood pressure medications and to prevent long-term risks many anti platelets are also prescribed in earlier stages and this preventive prescribing has emerged as a significant growth driver.

How Does the Cardiac Medicine Market in India Compare Globally?

If we think globally, then cardiovascular therapies are one of the largest segments in the pharmaceutical industry.

India follows these global patterns as well. But this is where they come with stronger momentum. Comparing these are some of the factors that in fact contribute to the higher growth rates:

• Urbanization
• Rising disposable income
• Lifestyle shifts
• Expanding healthcare infrastructure

The cardiac drug market in India continues to record a stronger double digit performance which shows its evolving healthcare ecosystem.

Future Outlook of the Cardiac Medicine Market in India (2025 to 2030)

If we look ahead, then the cardiac medicine market in India can be seen to be positioned for continued expansion.

There are several reasons that support this forecast:

• The aging population
• The lifestyle risk factors
• The penetration of health insurance
• The domestic pharmaceutical manufacturing base

It appears that the cardiovascular drug market is one of the most significant revenue contributors if the trend continues. That is if you see it within India’s pharmaceutical sector through 2030.

What Are The Strategic Implications for Healthcare Stakeholders?

The sustained growth rate of the cardiac medicine market actually offers you meaningful insight. Cardiac medicine market suggests:

• Chronic disease management will remain central to pharmaceutical demand.
• Preventive cardiology will continue to influence prescription writing.
• The depth of distribution and reach of market will play an increasingly important role in determining competitive advantage.
• Cardiovascular therapies will continue to be the prime revenue drivers in the Indian pharmaceutical industry.

Are you an observer of healthcare and industry dynamics? Then this segment is a public health signal. Apart from this, it has long term market opportunity.

Conclusion

From 2014 to 2024, the Indian cardiac medicine market has moved from a state of steady growth to structural growth. The significance of this market is evident. From the last decade it has increased threefold.

FAQs about Growth Rate Of Cardiac Medicine Market In The Last Decade

Q – What is the growth rate of the cardiac medicine market in India in the last decade?

A – The market has expanded about more than threefold over the past decade. There’s a recent five year CAGR of about 10 to 11%. This is based on industry reporting.

Q – What’s the current market size of the cardiac medicine market in India?

A – Recent data shows the cardiac segment which is valued at about ₹30,000 crore as of 2024.

Q – Why is the cardiovascular drug market growing rapidly in India?

A – Rising hypertension prevalence, longer treatment durations and preventive cardiology are the key drivers.

Q – Which segments dominate the cardiac pharmaceutical market in India?

A – Anri hypertensives, statins and heart failure drugs are some of what forms the largest revenue contributors.

Q –  Will the cardiac medicine market in India continue to grow till 2030?

A – That is possible if you look at the demographic trends and chronic disease prevalence. So, it may happen through the end of the decade.

Q – How does cardiac medicine growth compare to other therapy areas in India?

A – Cardiac therapies are always among the leading growing segments in the pharmaceutical industry.